Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection

American Journal of Transplantation

Volumn 16, Issue 4, 2016, Pages 1183-1192

  Reeve, J ^a   Chang, J ^a   Salazar, I D R ^a,c   Lopez, M Merino ^a   Halloran, P F ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Project Pacer International Boston   (Bolivia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; PANEL REACTIVE ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ALGORITHM; ARTERITIS; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GRAFT REJECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INFLAMMATION; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOM FOREST; SCORING SYSTEM; T CELL MEDIATED GRAFT REJECTION; AREA UNDER THE CURVE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; METABOLISM; MOLECULAR DIAGNOSIS; PHENOTYPE; PROGNOSIS; T LYMPHOCYTE;

AREA UNDER CURVE; BIOMARKERS; GENE EXPRESSION PROFILING; GRAFT REJECTION; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; T-LYMPHOCYTES;

EID: 84953322323     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13572     Document Type: Article

References (46)

1. Carrel A., Suture of blood-vessels and transplantation of organs. 11-12-1912. Nobel Media AB. Available from: http://www.nobelprize.org/nobel-prizes/medicine/llaureate/1912/carrel-lecture.html.
2. Gorer PA., The antigenic structure of tumors. Adv Immunol 1961; 1: 345-393.
3. Solez K, Axelsen RA, Benediktsson H, et al., International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422.
4. Halloran PF., T cell mediated rejection of kidney transplants: A personal viewpoint. Am J Transplant 2010; 10: 1126-1134.
5. Venner JM, Famulski K, Badr D, Hidalgo LG, Chang J, Halloran PF., Molecular landscape of T cell-mediated rejection in human kidney transplants: Prominence of CTLA4 and PD ligands. Am J Transplant 2014; 14: 2565-2576.
6. Marcussen N, Lai R, Olsen TS, Solez K., Morphometric and immunohistochemical investigation of renal biopsies from patients with transplant ATN, native ATN, or acute graft rejection. Transplant Proc 1996; 28: 470-476.
7. Salazar IDR, Lopez MM, Chang J, Halloran PF., Reassessing the significance of v-lesions in kidney transplant biopsies. J Am Soc Nephrol 2015
8. Lefaucheur C, Loupy A, Vernerey D, et al., Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313-319.
9. Yu F, Wu LH, Tan Y, et al., Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010; 77: 820-829.
10. Ferrario F, Vanzati A, Pagni F., Pathology of ANCA-associated vasculitis. Clin Exp Nephrol 2013; 17: 652-658.
11. Sis B, Mengel M, Haas M, et al., Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10 (Suppl 3): 464-471.
12. Saad R, Gritsch HA, Shapiro R, et al., Clinical significance of renal allograft biopsies with "borderline changes," as defined in the Banff Schema. Transplant 1997; 64: 992-995.
13. Meehan SM, Siegel CT, Aronson AJ, et al., The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. J Am Soc Nephrol 1999; 10: 1806-1814.
14. Schweitzer EJ, Drachenberg CB, Anderson L, et al., Significance of the Banff borderline biopsy. Am J Kidney Dis 1996; 28: 585-588.
15. de Freitas DG, Sellares J, Mengel M, et al., The nature of biopsies with "borderline rejection" and prospects for eliminating this category. Am J Transplant 2012; 12: 191-201.
16. Solez K, Colvin RB, Racusen LC, et al., Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
17. Reeve J, Sellares J, Mengel M, et al., Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13: 645-655.
18. Halloran PF, Pereira AB, Chang J, et al., Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 2013; 13: 2352-2363.
19. Mengel M, Chan S, Famulski K, et al., Increased tubular protein expression of integrin-beta 6 in implantation biopsies from human renal allografts is associated with increased tissue injury and impaired immediate allograft function. Am J Transplant 2012; 12 (Suppl 3): 165.
20. Haas M, Sis B, Racusen LC, et al., Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
21. Wu KY, Budde K, Schmidt D, Neumayer HH, Rudolph B., Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. Clin Transplant 2014; 28: 410-418.
22. Sis B, Bagnasco SM, Cornell LD, et al., Isolated endarteritis and kidney transplant survival: A multicenter collaborative study. J Am Soc Nephrol 2015; 26: 1216-1227.
23. Halloran PF, Chang J, Famulski K, et al., Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol 2015; 26: 1711-1720.
24. Halloran PF, Salazar IDR, Merino Lopez M, Chang J., The occurrence of v-lesions is not associated with decreased graft survival. Am J Transplant 2015; 15 (Suppl 3). http://www.atcmeetingabstracts.com/abstract/the-occurrence-of-v-lesions-is-not-associated-with-decreased-graft-survival/.
25. Halloran PF, Salazar IDR, Merino Lopez M, Chang J., Reassessing tubulitis and interstitial infiltrate: Creating a new probabilistic definition of TCMR. Am J Transplant 2015; 15 (Suppl 3). http://www.atcmeetingabstracts.com/abstract/reassessing-tubulitis-and-interstitial-infiltrate-creating-a-new-probabilistic-definition-of-tcmr/.
26. Sellares J, Reeve J, Loupy A, et al., Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
27. Halloran PF, Pereira AB, Chang J, et al., Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant 2013; 13: 2865-2874.
28. Halloran PF, Chang J, Famulski K, et al., Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol 2015; 26: 1711-1720.
29. Robin X, Turck N, Hainard A, et al., pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77.
30. Haas M., Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant 2014; 18: 319-326.
31. Sellares J, de Freitas DG, Mengel M, et al., Inflammation lesions in kidney transplant biopsies: Association with survival is due to the underlying diseases. Am J Transplant 2011; 11: 489-499.
32. Limmathurotsakul D, Turner EL, Wuthiekanun V, et al., Fool's gold: Why imperfect reference tests are undermining the evaluation of novel diagnostics: A reevaluation of 5 diagnostic tests for leptospirosis. Clin Infect Dis 2012; 55: 322-331.
33. Brealey SD, Scally AJ, Hahn S, Godfrey C., Evidence of reference standard related bias in studies of plain radiograph reading performance: A meta-regression. Br J Radiol 2007; 80: 406-413.
34. Waikar SS, Betensky RA, Emerson SC, Bonventre JV., Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol 2012; 23: 13-21.
35. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM., Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007; 11: iii, ix-51.
36. Reitsma JB, Rutjes AW, Khan KS, Coomarasamy A, Bossuyt PM., A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol 2009; 62: 797-806.
37. Sellares J, Reeve J, Mengel M, Famulski K, Hidalgo L, Halloran PF., Predictors of response to treatment in biopsy-diagnosed T cell-mediated rejection. Am J Transplant 2012; 12 (Suppl 3): 322.
38. Loupy A, Vernerey D, Tinel C, et al., Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015; 26: 1721-1731.
39. Reeve J, Halloran PF, Kaplan B., Common errors in the implementation and interpretation of microarray studies. Transplant 2015; 99: 470-475.
40. Rush D, Arlen D, Boucher A, et al., Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538-2545.
41. El-Zoghby ZM, Stegall MD, Lager DJ, et al., Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
42. Matignon M, Muthukumar T, Seshan S, Suthanthiran M, Hartono C., Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplant 2012; 94: 603-611.
43. Moreso F, Ibernon M, Goma M, et al., Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752.
44. Naesens M, Kuypers DR, De Vusser K, et al., Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 2013; 13: 86-99.
45. Mengel M, Chang J, Kayser D, et al., The molecular phenotype of six-week protocol biopsies from human renal allografts: Reflections of prior injury but not future course. Am J Transplant 2011; 11: 708-718.
46. Wiebe C, Gibson IW, Blydt-Hansen TD, et al., Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015; 15: 2921-2930.